OBJECTIVE: The combination of oxaliplatin and oral capecitabine (XELOX) has shown to be
an active regimen in metastatic colorectal cancer (MCRC). However, the experience with …

Background We evaluated which patient factors were associated with treatment tolerance
and outcome in elderly colon cancer patients. Design Population-based data from five …

Previous studies have reported improved outcomes for elderly patients with metastatic
colorectal cancer (mCRC) treated with oxaliplatin or irinotecan as first-line chemotherapy …

Objective: Colorectal cancer is the third most commonly reported cancer in the world and
about 50% of patients are diagnosed over the age of 70 years. The authors discuss age …

Background The purpose of this observational study was to evaluate feasibility, efficacy
results and toxicity observations of capecitabine in routine first line treatment of patients with …

Dear Editor: The study of Nitsche et al.(Int J Colorectal Dis. 2014; 29: 971–979) focusing on
elderly patients who underwent surgery for colorectal cancer confronts us with two problems …

Adjuvant chemotherapy improves the prognosis of patients with colorectal cancer (CRC)
following radical resection. The aim of the present study is to review appropriate …

Introduction The clinical benefit of double-front-line therapy (including oxaliplatin or
irinotecan or bevacizumab plus 5-fluorouracil (5FU) or capecitabine) compared to …

Objective We aim to examine the use and outcomes of adjuvant chemotherapy in older
patients with stage II and III colon cancer. Material and Methods Using data from the SEER …

Objective Randomized trials have established the effectiveness of 5-fluorouracil-based
adjuvant chemotherapy for stage III resectable colon cancer but the toxicity has not been …